Caliway Biopharmaceuticals C stock has November 11, 2026 results
Published on 10/15/2026 at 15:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and valuation
- Caliway Biopharmaceuticals C is scheduled to report results on November 11, 2026.
- The stock's 52-week low is TWD 75.10 as of October 15, 2026.
- Caliway Biopharmaceuticals C stock costs TWD 75.30 at 1:30 p.m. TST on October 15, 2026, down 3.83 percent versus the prior close of TWD 78.30.
- The market capitalization is TWD 117.2 billion and the price-to-earnings ratio is minus 466.83.
Caliway Biopharmaceuticals C has its next results scheduled for November 11, 2026, according to Investing.com. The Taiwan-listed stock then stood at TWD 75.30 at 1:30 p.m. TST on October 15, 2026, down 3.83 percent from its prior close of TWD 78.30.
November 11 results date
The scheduled reporting date gives investors the next fixed calendar point for Caliway. Investing.com lists November 11, 2026, for the report covering the period ended September 2026. The prior published report covered the period ended June 2026 and was released on August 4, 2026.
The latest reported quarter brought revenue of TWD 3.57 million and a net loss of TWD 222.52 million, according to Investing.com. Revenue was below the listed TWD 6.01 billion estimate, while adjusted earnings per share were minus TWD 0.14 against a TWD 2.91 estimate for the period ended June 2026.
The price nears its low
At TWD 75.30, the stock was 0.27 percent above its 52-week low of TWD 75.10 and 59.95 percent below its 52-week high of TWD 188.00 as of October 15, 2026. The session ranged from TWD 75.10 to TWD 78.30, placing the latest price at the bottom of that daily band.
Trading volume reached 3,517,264 shares against an average of 6,784,119 shares. That places the session volume 48.18 percent below the average. The company is listed on the Taiwan Stock Exchange under ticker 6919, as stated in its September 23, 2026 release from Caliway Biopharmaceuticals.
Valuation and the next report
Caliway's market capitalization was TWD 117.2 billion as of October 15, 2026. Its price-to-earnings ratio was minus 466.83, reflecting the reported loss, while the dividend yield was 0.00 percent.
Comparison with peers
Caliway Biopharmaceuticals C: minus 3.83 percent, P/E minus 466.83, market capitalization TWD 117.2 billion.
PharmaEssentia Corporation (TWSE, TWD): plus 1.26 percent, P/E 60.64, market capitalization TWD 497.1 billion.
Bora Pharmaceuticals (TWSE, TWD): minus 0.12 percent, P/E 35.22, market capitalization TWD 54.0 billion.
Market position
The price sits near the lower boundary of its annual range while the next report is dated November 11, 2026. The company identifies itself as a pharmaceutical developer, and its investor page lists ticker 6919 and financial statements among its investor materials.
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
